These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 39315676)
1. Real-world assessment of comprehensive genome profiling impact on clinical outcomes: A single-institution study in Japan. Kunimasa K; Sugimoto N; Yamasaki T; Kukita Y; Fujisawa F; Inoue T; Yamaguchi Y; Kitasaka M; Sakai D; Honma K; Wakamatsu T; Yamamoto S; Hayashi T; Mabuchi S; Okuno J; Kawamura T; Kai Y; Urabe M; Nishimura K Cancer Med; 2024 Sep; 13(18):e70249. PubMed ID: 39315676 [TBL] [Abstract][Full Text] [Related]
2. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889 [TBL] [Abstract][Full Text] [Related]
3. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376 [TBL] [Abstract][Full Text] [Related]
4. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. Kubo T; Sunami K; Koyama T; Kitami M; Fujiwara Y; Kondo S; Yonemori K; Noguchi E; Morizane C; Goto Y; Maejima A; Iwasa S; Hamaguchi T; Kawai A; Namikawa K; Arakawa A; Sugiyama M; Ohno M; Yoshida T; Hiraoka N; Yoshida A; Yoshida M; Nishino T; Furukawa E; Narushima D; Nagai M; Kato M; Ichikawa H; Fujiwara Y; Kohno T; Yamamoto N ESMO Open; 2024 Apr; 9(4):102981. PubMed ID: 38613908 [TBL] [Abstract][Full Text] [Related]
5. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291 [TBL] [Abstract][Full Text] [Related]
6. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057 [TBL] [Abstract][Full Text] [Related]
7. Identification of barriers to implementation of precision oncology in patients with rare cancers. Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548 [TBL] [Abstract][Full Text] [Related]
8. An approach for improvement of the accuracy of cancer gene panel testing. Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663 [TBL] [Abstract][Full Text] [Related]
9. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. Sunami K; Naito Y; Aimono E; Amano T; Ennishi D; Kage H; Kanai M; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Yoshino T Int J Clin Oncol; 2021 Mar; 26(3):443-449. PubMed ID: 33385275 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer. Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138 [TBL] [Abstract][Full Text] [Related]
11. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities. Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099 [TBL] [Abstract][Full Text] [Related]
12. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. Kikuchi J; Ohhara Y; Takada K; Tanabe H; Hatanaka K; Amano T; C Hatanaka K; Hatanaka Y; Mitamura T; Kato M; Shibata Y; Yabe I; Endoh A; Komatsu Y; Matsuno Y; Sugiyama M; Manabe A; Sakurai A; Takahashi M; Naruse H; Torimoto Y; Dosaka-Akita H; Kinoshita I Jpn J Clin Oncol; 2021 Apr; 51(5):753-761. PubMed ID: 33532831 [TBL] [Abstract][Full Text] [Related]
14. Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan. Yamaguchi T; Ikegami M; Aruga T; Kanemasa Y; Horiguchi SI; Kawai K; Takao M; Yamada T; Ishida H Int J Clin Oncol; 2024 Oct; 29(10):1417-1431. PubMed ID: 38795236 [TBL] [Abstract][Full Text] [Related]
15. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672 [TBL] [Abstract][Full Text] [Related]
16. Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy. Wiedower JA; Forbes SP; Tsai LJ; Liao J; Raez LE J Manag Care Spec Pharm; 2024 Jul; 30(7):660-671. PubMed ID: 38950156 [TBL] [Abstract][Full Text] [Related]
17. Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences. Tóth E; Kürönya Z; Soós E; Pintér T; Butz H; Horváth Z; Csernák E; Grolmusz VK; Székely J; Straussz T; Lövey J; Jánvári L; Báthory-Fülöp L; Nagy P; Polgár C; Patócs A Acta Oncol; 2024 Jun; 63():433-440. PubMed ID: 38881341 [TBL] [Abstract][Full Text] [Related]
18. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885 [TBL] [Abstract][Full Text] [Related]
19. Availability of genome-matched therapy based on clinical practice. Hayashi N; Mori S; Ohmoto A; Fukada I; Yamazaki M; Hosonaga M; Wang X; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Takahashi S Int J Clin Oncol; 2024 Jul; 29(7):964-971. PubMed ID: 38668785 [TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan. Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]